PLUS1
25.83
-0.12 (-0.46%)
-0.12 (-0.46%)
Upgrade to Real-Time
Afterhours (Closed)
Low
15.21
High
52.38
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Nurix Therapeutics Inc | NRIX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.12 | -0.46% | 25.83 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 25.90 | 25.48 | 27.55 | 25.83 | 25.95 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 21.03 | 30.32 | 9.29 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,139 | 212,507 | $ 26.24 | $ 5,575,285 | 357,173 | 15.21 - 52.38 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:05:50 | priorref | 334 | $ 25.83 | USD |
Nurix Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.15B | 44.35M | 31.04M | $ 17.82M | $ - | -2.74 | -7.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | -21.40k | 0.90% |
Nurix Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRIX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 26.78 | 28.07 | 24.55 | 26.06 | 334,784 | -0.95 | -3.55% |
| 1 Month | 28.76 | 36.04 | 24.55 | 29.96 | 327,999 | -2.93 | -10.19% |
| 3 Months | 36.51 | 47.84 | 24.55 | 33.20 | 488,831 | -10.68 | -29.25% |
| 6 Months | 32.15 | 52.38 | 24.55 | 35.64 | 389,446 | -6.32 | -19.66% |
| 1 Year | 20.25 | 52.38 | 15.21 | 33.30 | 311,062 | 5.58 | 27.56% |
| 3 Years | 20.25 | 52.38 | 15.21 | 33.30 | 311,062 | 5.58 | 27.56% |
| 5 Years | 20.25 | 52.38 | 15.21 | 33.30 | 311,062 | 5.58 | 27.56% |
Nurix Therapeutics Description
| Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. |
